STAT Plus: Alnylam and Dicerna, onetime rivals, announce a ceasefire
Rival biotechs Alnylam and Dicerna are announcing a ceasefire. The two companies, which are both…
Category: biotechnology
.jpg)
STAT Plus: Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer
Immunomedics is stopping a Phase 3 clinical trial due to “compelling evidence of efficacy” demonstrated…
This tiny federal agency was built to respond to a crisis like coronavirus. Now that it’s here, is BARDA ready?
WASHINGTON — It seems like an agency tailor-made for a crisis like the coronavirus pandemic….
STAT Plus: The latest failure in Alzheimer’s casts doubt on Biogen’s ostensible success
The prevailing theory of how to treat Alzheimer’s disease endured its 1,001st cut on Thursday,…
STAT Plus: Big biotech venture funds raise billions despite coronavirus fears
The economy is grinding to a near-halt because of Covid-19. In the biotechnology sector, which…
STAT Plus: The biotech scorecard for the second quarter: 18 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the second…
Rudy Giuliani wants FDA to fast-track a stem cell therapy for Covid-19; critics see political meddling
Rudy Giuliani, President Trump’s personal attorney, is urging the Food and Drug Administration to fast-track…
Amarin loses legal fight over heart drug patent; shares sink
Amarin shares fell sharply Monday evening after a federal judge ruled that key patents covering…
Biotech VC Bob Nelsen called it right on the coronavirus. Now he has thoughts on therapeutics — and masks
Bob Nelsen was right. The co-founder and managing partner of Arch Venture Partners is one…
STAT Plus: Could real-world evidence help shape the future of drug development?
Real-world evidence has been generating a stir in the world of drug development — and…
STAT Plus: STAT Plus video chat: Biotech in uncharted territory
Every corner of the biotech industry is being impacted by the coronavirus pandemic. There will…
What it’s like to go into the lab at a biopharma company during the coronavirus pandemic
Like grocery store clerks and Amazon delivery drivers, they’re among the essential workers of the…
Vir Biotechnology reports early progress in antibody treatment for Covid-19
Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of…
STAT Plus: Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead
Yesterday, I found out that I’m an “essential person” under Massachusetts’ new stay-at-home order. Should…
STAT Plus: Bellus Health hopes to be one of biotech’s more improbable turnarounds
About a dozen years ago, Bellus Health was teetering on the brink of insolvency after a would-be…
STAT Plus: Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors
When Michael Klichinsky was rotating through University of Pennsylvania hospitals as a pharmacy student more…
As Covid-19 spreads, disruptions to clinical trial and drug development accelerate
The disruption of clinical trials due to the novel coronavirus pandemic is becoming an almost…
Gilead suspends access to experimental Covid-19 drug due to ‘overwhelming demand’
Gilead Sciences has temporarily stopped granting patients access to remdesivir, its experimental drug against the…
Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?
In the 1995 movie “Outbreak,” doctors whip up a serum from monkey blood in just…
STAT Plus: Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too
Back again with another semi-regular column on the Covid-19 pandemic. You can read my first…
.jpg)
STAT Plus: Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval
After meeting with the Food and Drug Administration, Sage Therapeutics said Wednesday that it will…
Near-lockdown in the Bay Area ‘ratchets up’ challenges for local biotechs and labs
At the stroke of midnight on Tuesday morning, seven counties in the San Francisco Bay…
STAT Plus: Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers
This is the first in a series of semi-regular columns on the Covid-19 pandemic. In…
STAT Plus: Merck drug reduces cough frequency but taste alterations could cloud prospects
An experimental pill from Merck significantly reduced the frequency of chronic coughing compared to a…
Regeneron says potential Covid-19 drugs could start human tests by early summer
The biotechnology firm Regeneron said it has now developed hundreds of potential medicines that could…
STAT Plus: As the market craters, Keros Therapeutics files for an IPO
Keros Therapeutics is filing for an IPO, according to plans made public Monday — a…
Drug makers grounding salespeople as coronavirus impact on business spreads
In another sign that the coronavirus pandemic is fundamentally interrupting the way biopharma conducts business,…
How one company made $208 million on an untested coronavirus vaccine
Inovio Pharmaceuticals (INO), a drug company that has existed for four decades without developing an…
STAT Plus: Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers
Four years after it was founded, Kymera Therapeutics said Thursday that it has now raised…
STAT Plus: Engage touts long-awaited positive data for its inhaler for seizures
After scrabbling for early financing, Engage Therapeutics has some positive clinical data to show the…
Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals
As they race to test an experimental coronavirus vaccine, researchers aren’t waiting to see how…
STAT Plus: Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst
Biotech: Disrupted. As the number of Covid-19 cases expand globally, every corner of the biotech…
STAT Plus: FDA rejects Intarcia’s diabetes implant for a second time
For the second time, the Food and Drug Administration rejected an Intarcia Therapeutics implant aimed…
Pace of medical conference shutdowns is accelerating as the coronavirus outbreak spreads
Tanat Chinbunchorn, a physician and HIV prevention researcher, was mid-flight between Bangkok, Thailand, and Boston…
To develop a coronavirus vaccine, synthetic biologists try to outdo nature
Even as companies rush to develop and test vaccines against the new coronavirus, the Bill…
STAT Plus: Pharmalittle: Former Gates Foundation chief is ‘very worried’ about coronavirus; FDA does little to clarify CBD rules
And so, another working week will soon draw to a close. Not a moment too…
Listen: Pharma’s response to coronavirus, Google’s appetite for health data, and biotech’s rise in China
Does “The Art of the Deal” cover vaccines? Is patient privacy a relic of the…
STAT Plus: Gene and cell therapies continue growth in patients, financing, and costs
The number of people treated with approved gene therapies and gene-modified cell therapies like CAR-T…
In its first use inside the human body, CRISPR genome editing tested as blindness therapy
Scientists say they have used the gene editing tool CRISPR inside someone’s body for the…
STAT Plus: This biotech went public during the stock market’s worst week since 2008
Concerns about the coronavirus outbreak made last week one of the markets’ worst since the…
STAT Plus: TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
TG Therapeutics (TGTX) on Tuesday delayed yet again the readout from its most important blood…
STAT Plus: Thermo Fisher buys Dutch diagnostics company for $11.5 billion
Thermo Fisher Scientific (TMO) is buying the Dutch diagnostics company Qiagen (QGEN) in an $11.5…
Trump’s tone toward pharma shifts, as he looks to drug makers to help with coronavirus response
WASHINGTON — President Trump had billed the meeting with pharmaceutical executives as a scolding waiting…
A detailed guide to the coronavirus drugs and vaccines in development
In the months since the novel coronavirus rose from a regional crisis to a global…
STAT Plus: CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven
Gilead’s board hired CEO Dan O’Day a year ago to look for new areas of…
STAT Plus: Karyopharm to seek expanded use of multiple myeloma drug following positive clinical trial
Karyopharm Therapeutics (KPTI) said Monday that the primary goal was achieved in a clinical trial…
STAT Plus: Something Ventured: Vor Biopharma and 3 other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups….
Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease
The drug maker Biogen announced late Thursday that it would license two preclinical drugs from…
STAT Plus: Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug
Allakos (ALLK) is embroiled in a clinical trial controversy with potentially billions of dollars at…
STAT Plus: College student with disease that causes premature aging is heartened by medical advances
In many ways, Emerson College freshman Meghan Waldron seems like a lot of students in…